Endoscopic Cryotherapy of Lung and Bronchial Tumors: A Systematic Review by Lee, Seon-Heui et al.
ORIGINAL ARTICLE ORIGINAL ARTICLE
DOI: 10.3904/kjim.2011.26.2.137  
Endoscopic Cryotherapy of Lung and Bronchial Tumors: 










1National Evidence-Based Healthcare Collaborating Agency, Seoul; Departments of 2Thoracic and Cardiovascular Surgery and 
3Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea School of Medicine, Seoul; 4Department of 
Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea School of Medicine, Suwon; 5Center for Lung Cancer, 
Research Institute and Hospital, National Cancer Center, Goyang; 6Department of Pulmonary and Critical Care Medicine, Ajou 
University School of Medicine, Suwon, Korea
Background/Aims: We made a systematic review and evaluation of endoscopic cryotherapy of endobronchial tumors, 
investigating safety and efficacy.
Methods: Qualified studies regarding endoscopic cryotherapy of lung tumors were systemically evaluated using available 
databases according to predefined criteria.
Results: In total, 16 publications were included in the final assessment. A narrative synthesis was performed because a 
formal meta-analysis was not viable due to the lack of controlled studies and study heterogeneity. Overall success rates for 
significant recanalization of the obstruction were approximately 80%, although they varied, depending on disease status 
in the patient population. Complications from the procedure developed in 0-11.1% of cases, most of which were minor and 
controlled by conservative management. Although limited data were available on comprehensive functional assessment, 
some studies showed that respiratory symptoms, pulmonary function tests, and performance status were significantly 
improved.
Conclusions: Endoscopic cryotherapy was found to be a safe and useful procedure in the management of endobronchial 
tumors although its efficacy and appropriate indications have yet to be determined in well-designed controlled studies.
(Korean J Intern Med 2011;26:137-144 )
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INTRODUCTION
Despite recent development of therapies and anti-cancer 
drugs, lung cancer does not yet respond well to treatments 
and continues to have a poor prognosis. Accordingly, it 
is ranked first in the world in terms of mortality among 
malignant tumors [1-3].
Two-thirds of all lung cancers are already in a stage 
where surgery is difficult by the time of diagnosis, and 
conservative treatments play an important role. In 
approximately 30% of lung cancer patients, central airway 
obstruction is accompanied by symptoms such as dyspnea 
and hemoptysis. Local treatment for these symptoms 
plays an important role in alleviating patient symptoms 
and improving their quality of life [4]. In progressive lung 
cancers, accompanied by central airway obstruction, 
various interventional methods for improving airway 
obstruction have been tried, including Nd:YAG laser 
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therapy, electrocautery, brachytherapy, photodynamic 
therapy and cryotherapy [4,5]. Nd:YAG laser therapy, 
which has been widely used, and electrocauterization are 
effective and instantly open up the airway, but are more 
likely to result in such complications as airway perforation 
[5]. Also, photodynamic therapy is effective on small 
tumors, but is expensive, and may result in complications, 
including hemorrhage or secondary skin burns [5-7].
Cryotherapy uses flexible or rigid bronchoscopy to 
quickly freeze cells to -70ºC, destroying them. Although 
it has a relatively long history, it has been used less than 
other treatment methods [5,8]. This is believed to be 
attributed to the fact that its effect is more delayed and 
its indication narrower than the more popular Nd:YAG 
laser therapy. Several case studies have shown that 
endoscopic cryotherapy is fairly effective and safe, but 
its objective efficacy has not been proven through large-
scale controlled studies [9,10]. However, based on available 
research reports, endoscopic cryotherapy has a number of 
advantages: it is less expensive, and less likely to result in 
complications, such as perforation or hemorrhage. If it is 
used for appropriate indications, it is expected to establish 
itself as a useful interventional treatment method.
In this study, we systematically analyzed and evaluated 
research data on endoscopic cryotherapy, and discuss 
reference materials useful in the treatment of airway 
obstruction caused by tumors.
METHODS
Literature search strategy
The strategy to review the literature for ‘endoscopic 
cryotherapy performed on lung and bronchial tumors’ 
focused on studies that used the bronchoscope, and included 
studies that conducted a comparative analysis of laser 
therapy, electrocauterization, brachytherapy, stent insertion, 
and photodynamic therapy. After analysis, operation-related 
factors, such as safety, response, relapse, survival, and 
patient condition improvement factors, such as symptom 
improvement, pulmonary function, performance, quality of 
life, degree of bronchial obstruction, and oxygen saturation, 
were selected as major results.
Regarding ‘endoscopic cryotherapy for lung and bronchial 
tumors,’ eight domestic databases including KoreaMed and 
foreign databases like Ovid-Medline, EMBASE, CINAHL, 
and the Cochrane Library were used. The search strategy 
integrated ‘lung neoplasm, bronchogenic carcinoma, 
bronchial neoplasm and tracheal neoplasia’ and ‘cryotherapy, 
cryosurgery, cryoablation, cryocoagulation, cryodestruction 
and cryoextraction.’ In total, 664 documents in Korean 
and English were identified initially. Publications that 
were review articles, editorials, non-human experiments, 
preclinical studies, and documents containing abstracts 
only were excluded. In total, 648 documents, including 
210 overlapping documents, were excluded, leaving 16 
documents in the final evaluation. Each step, from literature 
review through application of selection criteria to data 
extraction, was carried out independently by a subcommittee 
and two evaluators. Scottish Intercollegiate Guidelines 
Network (SIGN) methodology was used to evaluate the 
quality of the literature, and levels of evidence and grades of 
recommendation were selected accordingly [11].
Study inclusion criteria
• Studies on lung and bronchial tumor patients.
• Studies on cryotherapy using bronchoscopy.
•   Studies in which more than one appropriate medical  
outcome was reported.
Study exclusion criteria
• Non-human and pre-clinical studies.
•    Studies that were not original articles (non-systematic 
reviews, editorials, letters, opinion pieces).
• Studies not published in Korean or English.
•   Cases where the effects of other therapies were mixed 
with that of cryotherapy.
• Studies that published abstracts only.
Effectiveness assessment of cryotherapy
The effectiveness of endoscopic cryotherapy for lung 
and bronchial tumors was evaluated on the basis of 
discussions of the subcommittee in terms of operation-
related factors and influences on the results of medical 
treatment. Operation-related factors included response, 
relapse, survival, and success rate, whereas influences on 
the results of medical treatment included improvement 
in clinical symptoms, pulmonary function, performance, 
quality of life, degree of bronchial obstruction, and the 
increase in oxygen saturation.
RESULTS
Literature search results
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used for the evaluation. The safety and effectiveness of 
endoscopic cryotherapy for the lung and bronchus were 
discussed in all 16 documents. Of the 16 selected reports, 
one was a comparison observation study with evidence 
level 2 [12], and the remaining 15 were case studies 
[9,10,13-25]. General characteristics of the studies are 
presented in Table 1.
Clinical data and outcomes
Safety
The safety of endoscopic cryotherapy for lung and 
bronchial tumors was evaluated on the basis of one 
comparison observation study, and 15 case studies with 
regard to deaths and complications within 30 days. 
Except for the small-scale study involving four subjects, 
complications, such as hemorrhage, mediastinal 
emphysema, atrial fibrillation, and dyspnea, occurred 
Table 1. General characteristics of studies selected for evaluation
Serial 
no.






1 2008 Jung et al. [13] 4 40-64 Advanced lung cancer: stage IIIb, 1; stage IV, 3 Case study
2 2007 Beeson [14] 645 68.3 Inoperable lung cancer due to advanced stage, poor     
 lung function or poor performance status
Case study
3 2006 Berotoletti et al. [15] 18 47 Typical carcinoid tumor Case study
4 2006 Zoganas et al. 
 [12] 163 67.9 Inoperable lung cancer due to advanced stage or 
 poor general conditions
Comparison 
observation
5 2005 Asimakopoulos et al. [9] 329 68 Inoperable lung cancer due to advanced stage, 
 poor lung function or poor performance status
Case study
6 2004 Hetzel et al. [16] 60 19-81 Endobronchial tumors: lung cancer; 56, benign 
 tumors, 3; malignant lymphoma 1
Case study
7 2004 Maiwand et al. [17] 521 67.9 Inoperable lung cancer due to advanced stage or 
 patients’ general conditions
Case study
8 2001 Deygas et al. [18] 35 61 Early superficial bronchogenic carcinoma that 
 cannot be operated due to comorbidities
Case study
9 2001 Noppen et al. [19] 15 63.5 Advanced lung cancer, 9; lung carcinoma in situ, 4; 
 hemangioma, 1; melanoma, 1
Case study
10 1999 Maiwand [10] 153 68.8 Inoperable lung cancer due to advanced stage, 
 site of the tumor, poor lung function or poor general 
 health
Case study
11 1996 Mathur et al. [20] 20 62 Inoperable endobronchial tumors: primary lung 
 cancer, 17; metastatic lung cancer, 3 
Case study
12 1993 Marasso et al. [21] 234 62 Lung tumors of various status: malignant tumors, 
 190; benign tumors, 44
Case study
13 1990 Walsh et al. [22] 33 75 Inoperable lung cancer due to advanced stage or 
 poor general conditions
Case study
14 1986 Homasson et al. [23] 22 39-88 Inoperable lung cancer due to advanced stage or 
 poor general conditions
Case study
15 1986 Maiwand [24] 75 63 Advanced lung cancer: previous surgery, 26; 
 previous radiotherapy, 16; cryotherapy as primary 
 therapy, 33
Case study
16 1981 Sanderson et al. [25] 28 63 Inoperable lung cancer due to advanced stage or 
 poor general conditions
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in 11.1% of all cases in 10 of the 16 studies. Most of the 
complications were controlled with simple conservative 
treatments (Table 2). In five of the 16 studies, mortality 
occurred in 7.1% of cases within 30 days of the operation. 
Causes of death were hemoptysis and respiratory failure. 
However, it was considered that most of the mortality 
was more likely to be associated with disease progression 
rather than a direct consequence of the procedures (Table 
3).
Response rate
The case study by Hetzel et al. [16] evaluated the 
response rate of endobronchial tumors accompanied by 
a high level of stenosis after cryotherapy; the complete 
response rate was 61% (37/60), the partial response rate 
was 22% (13/60), and the total response rate was 83%. 
Deygas et al. [18] performed cryotherapy in treating 35 
early superficial bronchogenic carcinoma patients who 
were inoperable due to comorbidities. The process was 
repeated 10-15 days later. They also followed 22 of the 35 
patients; as a result, the complete response rate after 1 year 
was 91% (32/35). Homasson et al. [23] performed three 
cycles of -80°C cryotherapy in 27 lung cancers including 
patients who underwent preoperative radiation treatment 
(n = 5), chemotherapy (n = 3), and chemoradiation therapy 
(n = 3). The procedure was repeated 4-6 days layer and 
the response rate was evaluated. The results showed that 
the response rate of malignant tumors was 61.9% (13/21), 
and that of benign tumors was 100% (5/5). In the case 
study by Jung et al. [13], endoscopic cryotherapy was 
performed on one stage IIIb, and three stage IV lung 
cancer patients, with a success rate of 75% (3/4). Noppen 
et al. [19] performed 3 × 20-s cycles of -80°C cryotherapy 
in five invasive lung cancer patients, four carcinoma in situ 
(CIS) patients, two metastatic cancer patients, and one 
hemangioma patient. The process was repeated 1-2 weeks 
later, and the success rate was evaluated. Results showed 
the success rate to be 80% (4/5) in lung cancer, and zero 
in metastatic lung cancer. In all cases where the operation 
needed to be repeated, the second operation was a success. 
In the case study by Beeson [14] -70°C cryotherapy was 
performed on 645 patients who were inoperable for 
various reasons. They reported that the tumor in the 
bronchus was reduced, and the airway was opened in most 
cases. Walsh et al. [22] performed three cycles of -70°C 
cryotherapy for 33 inoperable patients, and evaluated the 
degree of bronchial obstruction. The degree of bronchial 
Table 3. 30-day mortality after endoscopic cryotherapy
Year Author Occurrence (%)
2005 Asimakopoulos et al. [9]   9/32 (2.4)
2004 Maiwand et al. [17]   7/512 (1.2)
1999 Maiwand [10] 0/153 (0.0)
1986 Homasson et al. [23]  1/27 (3.7)
1981 Sanderson et al. [25]  2/28 (7.1)
Table 2. Complications of endoscopic cryotherapy
Year           Author Occurrence             Complications Treatment
2008 Jung et al. [13] 2/4 Mediastinal emphysema, hemoptysis Controlled by conservative management
2007 Beeson [14] Hemorrhage Controlled by conservative management
2006 Berotoletti et al. [15] 2/18 Hemorrhage, subcutaneous emphysema Controlled by conservative management
2005 Asimakopoulos et al. [9] 35/329 Hemorrhage, atrial fibrillation, dyspnea Controlled by conservative management
2004 Hetzel et al. [16] 10/60 Hemorrhage Controlled by hemostasis with plasma 
 beamer
2004 Maiwand et al. [17] 49/521 Hemoptysis, atrial fibrillation, dyspnea Transient and not serious complications
2001 Deygas et al. [18] 0/35
2001 Noppen et al. [19] 0/12
1999 Maiwand [10] 11/153 Hemorrhage, pneumothorax, anesthesia 
 complication
Controlled by conservative management
1990 Walsh et al. [22] 0/33
1986 Homasson et al. [23] 2/27 Light fever Transient
1986  Maiwand [24] 0/75Lee SH, et al. A systematic review of endobronchial cryotherapy    141
obstruction improved in 77% (20/26) of the patients, and, 
radiologically, atelectasis improved in 24% (7/24) of the 
patients.
Relapse rate
Hetzel et al. [16] reported a relapse rate of 24.6% 
(14/57) 10-24 weeks after cryotherapy in endobronchial 
tumors with obstruction. Deygas et al. [18] performed 
two successive sessions of cryotherapy for 35 superficial 
endobronchial tumors, and the relapse rate was 28% 
(10/35) after 13-45 months. According to the case study 
by Berotoletti et al. [15], three cycles of -70°C cryotherapy 
was performed for 18 typical carcinoid tumor patients. 
They were followed up for 44.5 months, and there was no 
relapse. However, after 7 years, two of the patients had 
relapsed (11.1%).
Survival rate
In the case study by Beeson [14], -70°C cryotherapy was 
performed on 645 patients who were inoperable. Among 
them, squamous cell carcinoma patients accounted for 
68.3%, adenocarcinoma 15.2%, large cell carcinoma 2.6%, 
undifferentiated carcinoma 5.2%, and small cell carcinoma 
8.7%. Patients in stage II accounted for 6.7%, stage IIIa 
21.0%, IIIb 23.9%, and stage IV 48.4%. This case study 
did not present comprehensive data on survival rates, but 
suggested the possibility of an increase in the survival 
rate due to the procedure. In the case study by Zoganas et 
al. [12], cryotherapy was performed for inoperable cancer 
patients, and the survival rate was analyzed 2 years later. 
The result showed that the survival rate was 19.3% in the 
group to which only cryotherapy was performed, and 25% 
in the group to which anticancer treatment was performed 
concurrently, but the difference was not statistically 
significant (p = 0.388). 
In the case study by Asimakopoulos et al. [9], cryotherapy 
was performed more than twice for advanced lung 
cancer patients. This group survived for 15 months, on 
average, whereas the other group for whom cryotherapy 
was performed only once survived for 8.3 months, on 
average. In the case study by Hetzel et al. [16], cryotherapy 
was performed on patients with protruding tumors 
accompanied with a high level of stenosis, and their 
survival rate after 36 weeks was 52.6% (30/57). Maiwand 
and Asimakopoulos [17] performed two sessions of 
cryotherapy for 521 cancer patients who were inoperable, 
and observed them for 18 months (4 to 84 months). 
Average survival was 8.2 months, and according to the 
stage, the average survival period of the patients was 15.1 
months in stage IIb, 8.5 months in stage IIIa, 9.0 months 
in stage IIIb, and 6.6 months in stage IV. Also, the 1-year 
survival rate was 38.4%, while the 2-year survival rate 
was 15.9%. Deygas et al. [18] followed up 22 of 35 early 
superficial cancer patients, and the 2-year survival rate 
was 62.5% (20/32), and after 48-89 months the survival 
rate was 50% (11/22). Six of the 19 died from other 
causes, six died of a relapse in the same location, and the 
remaining seven died of metastasis in other locations. 
Maiwand [24] performed two cycles of -70°C cryotherapy 
on 75 lung cancer patients with endobronchial tumors, 
who had undergone pneumonectomy (n = 18), preoperative 
radiation treatment (n = 16), and pneumonectomy and 
radiation treatment (n = 8), repeated for 2, 4, and 8 weeks, 
and followed them for 12 months. Results showed that the 
survival period of 19 patients was less than 1 month, 35 
patients survived for 1-5 months, six patients survived for 
6-11 months, and the remaining 16 patients survived for 12 
months or longer.
Improvement in clinical symptoms and pulmonary 
function
In most studies, the procedure was performed for 
advanced lung and bronchial cancer patients who were 
inoperable. Following the procedure, symptoms, such 
as dyspnea, cough, hemoptysis, and stridor, showed 
statistically significant improvements. This was also 
the case for pulmonary function; forced expiratory 
volume at 1 second (FEV1), forced vital capacity (FVC), 
and maximal flow rates showed statistically significant 
improvements after cryotherapy. The results of the studies 
are summarized in Table 4. Walsh et al. [22] reported 
that oxygen saturation (SaO2) improved in 77% (20/26) of 
patients.
Improvement in performance and quality of life
In the study by Maiwand and Asimakopoulos [17], 
performance status and quality of life were assessed before 
and after cryotherapy in 521 inoperable cancer patients. 
Results showed that the Karnofsky score improved 
significantly, from 60 to 75, and the WHO score was 
reduced significantly, from 3.04 to 2.20. Walsh et al. [22] 
reported that in 33 inoperable patients, the performance of 
27% (6/22) improved in the 6-minutes walking test. In the 
case study by Asimakopoulos et al. [9], cryotherapy was 
performed twice or more for Group A of advanced cancer 
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Group A were 67.7, 72.2, and 74.6 before cryotherapy, after 
the first cryotherapy and after the second cryotherapy, 
respectively, whereas the Karnofsky scores in Group B 
was 67.5, 74.6, and 73.6, respectively. Both groups showed 
statistically significant improvements.
DISCUSSION
We have discussed the available safety and efficacy 
data of cryotherapy in the treatment of the endobronchial 
tumors, although detailed and comprehensive analysis 
was not possible due to the variability of methodologies 
and lack of standardization of the procedures. According 
to this study, endoscopic cryotherapy generally showed 
high treatment efficiency in approximately 80% of cases, 
although there was variation depending on operation 
methods or target patient groups. It was also effective 
in improving quality of life, improving symptoms, like 
dyspnea, and improving pulmonary function. In lung 
tumors, airway obstruction is one of the symptoms seen 
in patients, but it has an important influence on quality 
of life, so appropriate treatment is required on many 
occasions, and although it may be difficult to expect that 
Table 4. Improvement in clinical symptoms and pulmonary function
Year           Author Operation method Improvement of clinical symptoms
Improvement of the pulmonary 
function
2008 Jung et al. [13] -89°C freezing for   
 5-20 sec, and thawing 
 repeated
Cases 1 and 2: dyspnea and 
 atelectasis improved; Case 3: 
 dyspnea improved
Not mentioned
2007 Beeson [14] -70°C FEV1 and FVC improved
2006 Zoganas et al. [12] Not mentioned Single: 65%; Concurrent
a: 80% Not mentioned
2005 Asimakopoulos et al. 
[9]
3-min, -70°C
2 times or more (Group 
 A), once (Group B)
Dyspnea improvement rate: Group A, 
 36.6%; Group B, 10.8%
Coughing improvement rate: Group A, 
 41.9%; Group B, 11.4%
Hemoptysis improvement rate: Group 
 A, 35%; Group B, 6%
Group A: significant 
 improvement of FVC
Group B: no significant 
 improvement of FVC or FEV1
2004 Maiwand et al. [17] 3-min, -70°C
2.4 times on average, 
 repeated 2 wk later
Cough, 69%; dyspnea, 59.2%; 
 hemoptysis, 76.4%; chest pain, 42%
Significant improvement of 
 FEV1 (1.39 → 1.51 L) and 
 FVC (1.93 → 2.13 L)
1990 Walsh et al. [22] 3-min, -70°C
3 times, repeated 2-4 
 wk later
Subjective improvement, 23/33 
 (70%); dyspnea score, 10/27 (37%); 
 hemoptysis, 6/9 (67%); stridor, 4/7 
 (56%)
Improvement rates: FEV1, 7/29 
 (24%); FVC, 7/29 (24%); 
 MEF, 6/29 (21%); 
 MIF, 3/11 (27%)
1986 Homasson et al. [23] 1-min, -80°C
3 times, repeated 4-6 
 days later
Favorable, 17: atelectasis improved 
 (15), hemoptysis improved (2);
 no benefit, 9: technical failure (5),  no 
 reaction (3), death before treatment (1)
Not mentioned
1986 Maiwand [24] 150 sec, -70°C
2 times, repeated 2, 4, 
 and 8 wk later
Symptom improvement: stridor, 20/33 
 (61%); dyspnea, 23/31 (74%); 
 hemoptysis, 11/11 (100%)
Not mentioned
1981 Sanderson et al. [25] 2-min, -160°C
3 times, performed 1-8 
 times
Favorable, 15/28 (53.6%): tumors 
 reduced (8), hemorrhage reduced (4), 
 airway opened (3); no benefit, 13/28 
 (46.4%)
Not mentioned
FEV1, forced expiratory volume at 1 sec; FVC, forced vital capacity; MEF, maximal expiratory flow rate; MIF, maximal inspiratory flow rate.
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such local treatment will ultimately improve the survival 
rate, it will play an important role in patient management 
and conservative treatment. Laser therapy has been the 
preferred treatment for airway obstruction due to tumors. 
This is perhaps because laser therapy can instantly and 
powerfully open up even severe obstructions [26-28]. 
Laser therapy is known to result in more complications, 
including hemorrhage and perforation. Cryotherapy can 
be said to be superior in terms of safety [5]. Photodynamic 
therapy is also a useful local treatment method for various 
purposes, including curative treatment of an early cancer 
in the airway or alleviation of airway obstruction, but 
it is relatively expensive, and pre-and post-operation 
management is cumbersome [29]. Other endobronchial 
local treatment methods, including brachytherapy and 
electric cauterization, are used, and these methods 
have their own strengths and weaknesses. Accordingly, 
several factors, such as the status of the patient’s 
disease, experience of the practitioner, and financial 
considerations, must be taken into account when any of 
these methods are selected.
As described previously, endoscopic cryotherapy may 
still be less researched and used than other treatment 
methods, including laser therapy. Because cryotherapy 
does not affect the cartilage or collagen in the bronchus, 
there is almost no risk of perforation, and, in this sense, 
it is safer than other methods, but it has less destructive 
power and its effect is delayed. Thus, its efficacy may 
be considered to be limited in cases with severe airway 
obstruction due to a large and extensive tumor [5]. As the 
spectrum of cryotherapy is about 5 mm, it is limited, and 
though it is possible to overcome this with repetition, there 
are other limitations. As laser therapy is more effective in 
opening up severe obstructions, it may be inappropriate to 
select cryotherapy as an initial treatment in such a case. It 
is recommended to perform laser therapy or cauterization 
first, and then cryotherapy as an additional treatment for 
the remaining tumor. It can also be a useful treatment 
method in removing early tumors limited to the airway [5]. 
As reports on the supplementary efficacy and synergistic 
effect of using cryotherapy together with anticancer 
chemotherapy or radiation treatment are published, the 
possibility of using it as part of concurrent treatments is 
also suggested [30,31].
Limitations of the analysis in this study relate to 
cryotherapy not being standardized; individual studies 
differed in research methods and frequencies, and the 
characteristics of patient groups varied. Thus, comprehensive 
statistical analysis was difficult. Accordingly, comprehensive 
statistical analysis was avoided in the results section, 
and we focused on describing the characteristics and 
results of each study. Additionally, both rigid and flexible 
bronchoscopy can be used for cryotherapy; depending 
on the choice, efficacy can vary. Because there are many 
different types of probe, there are slight differences in 
the mechanism of action and efficacy. Thus, there are 
limitations in comprehensively analyzing multiple studies 
[5].
In conclusion, endoscopic cryotherapy performed for 
endobronchial tumors is a safe and effective treatment 
method that will improve the symptoms, pulmonary 
function, and performance in patients with endobronchial 
obstruction, especially in inoperable cases. Given the lack 
of well-designed studies comparing it with other treatment 
methods, it must be objectively compared with other 
treatment methods and more cases need to be analyzed in 
future studies.
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